PDK1 inhibition has also received attention in SL melanoma drug screens, demonstrating synergy with PI3K pathway inhibition in PTEN wild‐type melanoma (Scortegagna et al., 2015), and may provide a viable treatment option. Here, PDK1 is linked to melanoma.